NCT02283814已完成1 期
A Phase-1, Open-label, Drug Interaction Study Between Eslicarbazepine Acetate 1200 mg and Topiramate 200 mg Following Multiple Dose Administrations in Healthy Male
Bial - Portela C S.A.0 个研究点目标入组 32 人开始时间: 2007年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 主要终点
- Cmax - the Maximum Plasma Concentration
研究概览
简要总结
Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers
详细描述
Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers: Group A: Pre-treatment with ESL, treatment with ESL and ascending doses of Topamax (TPM) in last phases; Group B: Pre-treatment with TPM, treatment with TPM and ascending doses of ESL in last phases
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer
- •Male aged of at least 18 years but not older than 45 years with a body mass índex (BMI) greater than or equal to 19 and below 30 kg/m
- •Clinical laboratory values within the laboratory's stated normal range; i f not within this range, they must be without any clinical significance (laboratory tests are presented in section 6.1.1.3)
- •Healthy according to the medical history, laboratory results and physical
- •Light-, non- or ex-smokers. A light smoker is defined as someone smoking 1 0 cigarettes or less per day, and an ex-smoker i s defined as someone who completely stopped smoking for at least 1 2 months before day 1 of this study
排除标准
- •Significant history of hypersensitivity to topiramate, eslicarbazepine, oxcarbazepine, carbamazepine or any related products (including excipients of the formulations) as wel l as severe hypersensitivity reactions (like angioedema) to any drugs
- •Presence of significant gastrointestinal, l iver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
- •History of significant gastrointestinal, liver o r kidney disease, o r surgery that may affect drug bioavailability, including but not limited to cholecystectomy
- •Presence of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic d isease
- •Presence o f significant heart disease o r disorder according to ECG
- •Presence or history of significant central nervous system disorder l ike convulsion or depression
- •Presence o r history o f significant ocular disease
- •Presence or history of severe hepatic impairment
- •Presence or history of renal insufficiency (serum creatinine level greater than 135 μmol/L)
- •History or presence of acidosis
- •Use of valproic acid in the previous 7 days prior to Day 1 of the study.
- •Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- •Any clinically significant illness in the previous 28 days before day 1 of this study
- •Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before Day 1 of this study
- •Participation in another clinical trial or donation of 50 mL or more of blood in the previous 28 days before day 1 of this study
- •Donation of 500 mL or more of blood (Canadian B lood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
- •Positive urine screening of drugs of abuse (drugs listing is presented in section 6.1.1.4).
- •Positive results to HIV, HBsAg or anti-HCV tests
研究组 & 干预措施
Group A BIA 2-093 + Topamax
Experimental
Group A
- Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;
- Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days
- Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days
- Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days
- Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days
干预措施: BIA 2-093 (Drug)
Group A BIA 2-093 + Topamax
Experimental
Group A
- Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;
- Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days
- Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days
- Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days
- Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days
干预措施: Topamax (Drug)
Group B BIA 2-093 + Topamax
Experimental
- Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;
- Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;
- Treatment: 200 mg once daily dose of TPM administered for four consecutive days;
- Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days
- Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days
干预措施: BIA 2-093 (Drug)
Group B BIA 2-093 + Topamax
Experimental
- Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;
- Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;
- Treatment: 200 mg once daily dose of TPM administered for four consecutive days;
- Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days
- Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days
干预措施: Topamax (Drug)
结局指标
主要结局
Cmax - the Maximum Plasma Concentration
时间窗: Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h
BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate
Tmax - the Time of Occurrence of Cmax
时间窗: Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h
BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate Both Groups A and B described in participant flow recieved BIA 2-093 and Topiramate. The results presented here are related with the different interventions in both groups
次要结局
- AUCτ - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.(Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h)
研究者
相似试验
已完成
1 期
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.EpilepsyNCT02283801Bial - Portela C S.A.32
已完成
1 期
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.EpilepsyNCT02283827Bial - Portela C S.A.32
已完成
1 期
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinElevated Lipoprotein(a)Cardiovascular DiseasesNCT03426033Akcea Therapeutics18
已完成
1 期
The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult VolunteersPeptic UlcerNCT02581696Boryung Pharmaceutical Co., Ltd24
已完成
1 期
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelElevated Lipoprotein(a)Cardiovascular DiseasesNCT03392051Akcea Therapeutics18